BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T205127
CREATED:20210329T142632Z
LAST-MODIFIED:20210329T142632Z
UID:29572-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Immunogenicity Summit
DESCRIPTION:The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate\, measure and predict immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges\, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on the latest approaches to predict\, measure and overcome every immunogenicity challenge you encounter. \nFocused specifically on examining gene therapy immunogenicity\, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity. \nJoin your peers online and discover: \n\nHow Chameleon Bioscience are developing an immune evasive AAV for repeat dosing\nThe impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon\nStrategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics\nPerformances of biosafety analytical assays commonly used in gene therapy development\nImmunogenicity risk assessment for AAV-based gene therapies with Roche\nHow to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis\nAAV capsid neutralizing antibodies and associated complement mediated immunotoxicties with IU Edu\nRegulatory considerations for immune responses to gene therapies with the US FDA\nRole of innate immunity in CD8+ T cell responses in AAV gene transfer with The NIH\nMitigation of AAV vector immunogenicity with tolerogenic nanoparticles with Selecta Bioscience\n\nView the full event guide now to find out more!
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-immunogenicity-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T205127
CREATED:20210416T073855Z
LAST-MODIFIED:20210416T073855Z
UID:29797-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Findings of the Skin Microbiome into Commercially Viable Therapeutics & Cosmetic Products That Improve Skin Health \nWith improvements in the tools and technologies that enable deeper analysis of the skin microbiome\, the community’s understanding of the skin microbiome is becoming clearer. This has led to the development of a number of breakthrough dermatological\, skincare and cosmetic solutions that tap into this ecosystem on our skin for improved health. \nHowever\, there still exists several unique areas of basic and clinical science within the skin microbiome field that need addressing before the true potential of this field is realized. \nCelebrating our fourth year\, the Microbiome Movement – Skin Health & Dermatology Summit continues to unite researchers from academia and industry to address the unique areas of scientific R&D\, as well as the consumer interfacing aspect of this industry. Bringing together 25+ expert speakers and 100+ key decision makers across 3 days\, we will hasten the development of microbiome-targeting therapeutics and cosmetics through a series of presentations\, panel discussions and networking opportunities. \nJoin us to fast-track the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing and product commercialization. \nTightly focused on translating academic discussions into cosmetic and therapeutic development\, this unrivalled program addresses the latest scientific findings and key translational challenges to aid the development of your scientifically validated skin microbiome products so you can bring them to the hands of patients and consumers faster.
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR